目的研究替吉奥联合紫杉醇对进展期胃癌的疗效和安全性。方法选择2013年9月-2015年12月在濮阳市油田总医院进行诊治的进展期胃癌患者80例,按随机数字表法分为两组。观察组给予替吉奥、顺铂联合紫杉醇治疗,对照组给予替吉奥和紫杉醇治疗。两组患者均以21 d为1个周期,均接受2个周期的治疗。观察两组患者的近期疗效、远期疗效和不良反应发生情况。结果观察组的有效率为52.50%（21/40）,明显高于对照组的40.00%（16/40）,两组比较差异显著（P<0.05）；两组的中位无进展生存时间、中位总生存时间和1年生存率相比无明显差异；两组患者主要的不良反应为骨髓抑制及消化道反应,且多为0~Ⅱ度。观察组的恶心呕吐反应与对照组相比明显较轻（P<0.05）,其他不良反应两组相比无明显差异。结论替吉奥、顺铂联合紫杉醇对进展期胃癌具有较好的临床疗效,且安全性较高,值得临床推广应用。

Objective To explore the clinical effect and safety of S-1 combined with paclitaxel in treatment of advanced gastric cancer. Methods 80 patients with advanced gastric cancer accepted in our hospital from Sep.2013 to Dec.2015 were selected and randomly divided into 2 groups. Patients in observation group were given S-1, cisplatin and paclitaxel, and patients in control group were given S-1 and paclitaxel. Then the short term and long term clinical effect and adverse reactions of 2 groups were compared. Results The total effective rate of observation group was 52.50% (21/40), which was obviously higher than 40.00% (16/40) of control group (P < 0.05). The median progression-free survival, median overall survival and 1 year survival rate of 2 groups had no great differences. The main adverse reaction of 2 groups were bone marrow suppression and gastrointestinal reactions of grade 0~Ⅱ. The grade of nausea and vomiting of observation group was much lighter than control group (P < 0.05). But the other adverse reaction of 2 groups had no differences. Conclusion Using S-1, cisplatin and paclitaxel has good effect in treatment of advanced gastric cancer, which is safety and worthy of clinical applications.